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The anti-inflammatory activity of licorice (LE) and roated licorice (rLE) extracts determined in the murine phorbol ester-induced
acute inflammation model and collagen-induced arthritis (CIA) model of human rheumatoid arthritis. rLE possessed greater
activity than LE in inhibiting phorbol ester-induced ear edema. Oral administration of LE or rLE reduced clinical arthritis score,
paw swelling, and histopathological changes in a murine CIA. LE and rLE decreased the levels of proinflammatory cytokines in
serum and matrix metalloproteinase-3 expression in the joints. Cell proliferation and cytokine secretion in response to type II
collagen or lipopolysaccharide stimulation were suppressed in spleen cells from LE or rLE-treated CIA mice. Furthermore, LE and
rLE treatment prevented oxidative damages in liver and kidney tissues of CIA mice. Taken together, LE and rLE have benefits in
protecting against both acute inflammation and chronic inflammatory conditions including rheumatoid arthritis. rLE may inhibit
the acute inflammation more potently than LE.
1. Introduction
Human rheumatoid arthritis (RA) is an autoimmune disease
associated with painful joints that aﬀects approximately 1%
of the worldwide population, for which there is no eﬀective
cure available [1, 2]. It arises from chronic joint inflam-
mation, which causes structural damage to cartilage, bone,
and ligaments [3]. Rheumatoid synovial tissue is central
to the pathogenesis of RA, as it becomes hyperplastic as a
result of the accumulation and proliferation of inflammatory
cells, including B cells, T cells, macrophages, and synovial
fibroblasts [3]. Infiltrating immune cells produce and release
a variety of cytokines, predominantly tumor necrosis factor
(TNF)-α and interleukin (IL)-1β, which attract and activate
other inflammatory cells, propagating a vicious inflamma-
tory cycle that leads to bone damage [4]. These cytokines
also increase the production of matrix metalloproteinases
(MMPs), enzymes that can degrade all components of the
extracellular matrix, leading to destruction of cartilage [5].
RA is widely treated with nonsteroidal anti-inflammatory
drugs, immunosuppressive disease-modifying anti-rheumat-
ic drugs and corticosteroids, which normalize the immune
system and reduce the expression of inflammatory mediators
[6, 7]. However, these drugs are undesirable for long-term
treatment due to low eﬃcacy, delayed onset of action, long-
term side eﬀects and toxicity [8]. Therapeutic targeting
of cytokines in RA using TNF-α and IL-1β antagonists
has substantial eﬃcacy, but this strategy is expensive and
has many side eﬀects, including hypersensitivity to medi-
cations and infections [8, 9]. Therefore, it is necessary to
develop preventive and therapeutic agents that have minimal
toxicity, and oriental natural medicinal plants with anti-
inflammatory activities are a useful resource to obtain novel
antiarthritic agents.
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Licorice is an esteemed crude drug that originates from
the dried roots of several Glycyrrhiza species [10]. Chinese
traditional medicine practitioners have used licorice to treat
various ailments ranging from tuberculosis to peptic ulcers
[11], and licorice has been employed as a flavoring and
sweetening agent as well as a demulcent and expectorant in
Western countries [12]. The roasted form of licorice has been
reported to possess anti-allergic [13], neuroprotective [14],
antioxidative [15], and anti-inflammatory activities [16]. In
the present study, we found that roasted licorice extract
(rLE) was more potent than unroasted licorice extract (LE)
in inhibiting ear edema in mice treated with phorbol ester,
which induces acute inflammation due to the increased activ-
ity of TNF-α and IL-1β [17]. Furthermore, we investigated
the antiarthritic eﬀects of rLE in a murine collagen-induced
arthritis (CIA) model that has been widely accepted as an
appropriate animal model of human rheumatoid arthritis
[18].
2. Materials and Methods
2.1. Reagents. LE and rLE were generously provided by
Lim, a coauthor [16]. Bovine collagen type II (CII),
complete Freund’s adjuvant (CFA) and incomplete Fre-
und’s adjuvant (IFA) were obtained from Chondrex (Red-
mond, WA). 12-O-tetradecanoylphorbol-13-acetate (TPA),
dimethyl sulfoxide (DMSO), lipopolysaccharide (LPS),
1,1,3,3-tetramethoxypropane, 5,5-dithiobis (2-nitrobenzoic
acid) (DTNB), and 4-amino-3-hydrazino-5-mercapto-1,2,4-
triazole (purpald) were purchased from Sigma-Aldrich
Chemical. (St. Louis, MO).
2.2. Animals. Female ICR mice (5 weeks old) and male
DBA/1J mice (7–9 weeks old) were obtained from Central
Laboratory Animal (Seoul, Korea) and the Jackson Labora-
tory (Bar Harbor, ME), respectively. All mice were permitted
free access to a normal standard chow diet and tap water, and
were housed at 20–22◦C, with a relative humidity of 55± 5%
and a 12-h light-dark cycle. Animal studies were conducted
in accordance with the guidelines for the use and care of
animals of Yonsei University (Seoul, Korea).
2.3. Determination of Anti-Inflammatory Activity. The right
ear of each ICR mouse (5 per group) was topically treated
with LE or rLE (1.0 and 2.0 mg/ear) in 50 μl vehicle (DMSO-
acetone: 15–85, v/v) 30 minutes prior to the application
of 5 nmol TPA in 50 μl vehicle. The left ears were treated
with vehicle alone, and control mice received only vehicle
on both ears. 4 hours later, right and left ear punches 6 mm
in diameter were taken from each mouse, and then weighed.
Edema was represented as the increase in weight of the right
ear punch over that of the left.
2.4. Determination of Antiarthritic Activity
2.4.1. Induction of CIA and Administration of Extracts.
DBA/1J mice were intradermally injected with 100 μg CII
in CFA (1 : 1, w/v) to the tail base, and boosted with an
intradermal injection of 100 μg CII in IFA (1 : 1, w/v) on
day 21. CIA mice were orally administered the vehicle (PBS
containing 1% DMSO), LE or rLE at 10 mg/kg once daily
from day 25, when the first clinical signs of arthritis were
observed, to day 45. Control mice were neither immunized
with CII nor treated with extracts. The development of
arthritis was evaluated by macroscopic scoring as follows:
0, normal; 1, swelling and/or redness in only one joint; 2,
swelling and/or redness in more than one joint; 3, swelling
and/or redness in the entire paw; and 4, severe swelling
of the entire paw with deformity and/or ankylosis. The
macroscopic arthritis score of each mouse was presented as
the sum of each score of the four limbs, with the maximum
score being 16. Paw swelling was assessed by measuring the
thickness of the two hind paws with a digital caliper every
other day from day 25. On day 45, all mice were sacrificed
after serum collection. Hind paw and knee joints, spleens,
livers and kidneys were removed from the control and CIA
mice.
2.4.2. Histopathological and Immunohistochemical Analysis.
The joint tissue sections were prepared and stained with
hematoxylin and eosin after routine fixation, decalcification,
and paraﬃn embedding. For immunohistochemical analysis,
the sections were sequentially incubated with a specific
primary antibody against MMP-3 (Santa Cruz Biotech-
nology, Santa Cruz, CA), and the appropriate horseradish
peroxidase-linked secondary antibody. All sections were
counterstained with hematoxylin.
2.4.3. Preparation of Spleen Single-Cell Suspensions. Spleens
were washed with cold PBS and dissociated into single cell
suspensions using cell strainers. Cells were cultured with
RPMI 1640 medium containing 50 μM 2-mercaptoethanol,
1% antibiotic-antimycotic mixture and 10% FBS.
2.4.4. Measurement of Cytokine Levels in Blood Serum and in
the Conditioned Medium of Spleen Cells. Serum was isolated
from all mice on day 45 as described previously [19]. Single-
cell suspensions (2 × 106 cells/well) were stimulated with
50 μg/ml denatured-CII or 5 μg/ml LPS for 48 hours at 37◦C
in a 5% CO2-humidified incubator. The conditioned media
was collected. TNF-α and IL-1β levels in the serum and in
the conditioned medium were assayed using commercially
available ELISA kits (R&D systems, Minneapolis, MN).
2.4.5. Spleen Cell Proliferation Assay. Spleen single-cell sus-
pensions (2 × 105 cells/well) were stimulated with 50 μg/ml
denatured-CII for 72 hours at 37◦C in a 5% CO2 humidified
incubator. Cell proliferation was measured using a BrdU
cell proliferation ELISA kit (Roche Diagnostics, Mannheim,
Germany).
2.4.6. Determination of the Protective Activity on CIA-Induced
Oxidative Tissue Damages. Lipid peroxidation, reduced glu-
tathione (GSH) level and catalase activity in the liver and
kidney homogenates were measured as described previously
[15]. Protein concentrations were measured using the BCA
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protein assay kit (Pierce, Rockford, IL). Malondialdehyde
(MDA) levels were measured in form of thiobarbituric acid
reactive substances at 532 nm. A standard curve was estab-
lished using 1,1,3,3-tetramethoxypropane, and the MDA
level was expressed as nmol/mg protein. GSH levels were
estimated at 412 nm colorimetrically after its complex for-
mation with DTNB, and expressed as nmol/mg protein. The
determination of catalase activity was based on the reaction
of the enzyme with methanol in an optimal concentration
of hydrogen peroxide. The formaldehyde produced was
measured with purpald at 540 nm, and catalase activity was
expressed as units/mg protein. One unit (U) of catalase
was defined as the amount of enzyme that results in the
formation of 1 nmol of formaldehyde per minutes at 25◦C.
2.5. Statistical Analysis. Data are expressed as mean ±
standard error (SE), and analyzed via one-way ANOVA with
multiple comparisons, followed by Tukey test. P values less
than .05 were considered to be statistically significant.
3. Results and Discussion
The present study is the first report to determine and com-
pare the antiarthritic activities and underlying mechanism
of LE and rLE in the CIA mouse model of human RA.
Licorice is used in alternative medicine to treat individuals
with gastric ulcers, bronchitis, arthritis, adrenal insuﬃ-
ciency and allergies [10, 20]. It contains diverse chemical
components including glycyrrhizin and its aglycone, as
well as species-specific flavonoids such as licochalcone A,
liquiritin, isoliquiritin and their corresponding aglycons
[10, 21, 22]. These flavonoids possess antioxidative [23,
24] and anticarcinogenic activities [25]. Recent studies
demonstrated that rLE showed more potent anti-allergic,
anti-diabetic, and anti-inflammatory eﬀects than LE [13,
20, 26], and had higher glycyrrhetinic acid and lower
glycyrrhizin content than LE [26]. We have confirmed,
using high-performance liquid chromatographic analysis,
that rLE contained more licochalcone A and less glycyrrhizin
and isoliquiritigenin. The amount of glycyrrhizin and
isoliquiritigenin was reduced by half but the amount of
licochalcone A was increased to 5-fold by roasting (data
not shown). In this study, we first evaluated the anti-
inflammatory activity of LE and rLE on TPA-induced ear
edema to predict their antiarthritic potential. Mouse ear
edema induced with topically applied TPA is an excellent
acute inflammation animal model, closely related with the
infiltration of neutrophil and macrophages, the induction of
proinflammatory cytokines including TNF-α and IL-1, and
the generation of ROS including superoxide anion, thereby
can be very useful short-term test to detect the agents with
anti-arthritic potential [27]. Pretreatment with LE or rLE
dose-dependently suppressed mouse ear edema induced with
topical application of TPA for 4 hours, and rLE showed
more potent inhibition of inflammation than LE, as shown in
Figure 1. Pretreatment with licochalcone A and glycyrrhizin,
not isoliquiritigenin, significantly inhibited TPA-induced ear
edema in mice (data not shown). The increased licochalcone
0
2
4
6
8
10
12
14
E
ar
ed
em
a
(m
g)
/p
u
n
ch
TPA
(5 nmol/ear)
Extracts
(mg/ear)
− + + + + +
− − 1 2 1 2
LE rLE
∗
∗ ∗
∗∗
Figure 1: Eﬀects of LE and rLE on TPA-induced mouse ear edema.
The right ear of each ICR mouse was topically treated with LE and
rLE (1.0 and 2.0 mg/ear) in 50 μl vehicle (DMSO-acetone: 15–85,
v/v) 30 minutes prior to the application of 5 nmol TPA in 50 μl
vehicle. The left ears were treated with vehicle alone. Four hours
later, edema was measured as the increase in the weight of the right
ear punch over that of the left. Data are expressed as means ± SE of
5 mice per group. ∗P < .005, ∗∗P < .0001 versus TPA alone-treated
group.
A by roasting may contribute to better anti-inflammatory of
rLE on TPA-induced acute inflammation as compared with
LE.
We further determined the eﬀects of LE and rLE on
chronic inflammatory diseases using a mouse CIA model.
Although the murine CIA model does not completely
recapitulate human RA, it is a useful tool for studying
inflammation, autoimmune arthritis, cartilage destruction,
and bone erosion [18]. Our data indicated that oral
administration of LE and rLE to CII-immunized mice
reduced the progression of arthritis by inhibiting the increase
in arthritis score and paw swelling, as compared to the
vehicle-treated immunized mice (Figure 2(a)). There was
no significant diﬀerence between the ability of LE and
rLE to inhibit CIA severity, but rLE seemed to suppress
early paw swelling more eﬀectively than LE. The joints
of the vehicle-treated mice had noticeable pathological
changes, including CIA-characteristic synovial hyperplasia,
infiltration of inflammatory cells into the joint cavity, and
extensive pannus formation. The destruction of articular
cartilage and subchondral bone was also observed in the joint
tissues of vehicle-treated CIA mice. The pathological events
apparent in vehicle-treated CIA mice were substantially
reduced in the joints of LE- and rLE-treated CIA mice
(Figure 2(b)). Furthermore, immunohistochemical analysis
indicated that the joint specimens from vehicle-treated CIA
mice strongly stained for MMP-3, which is a key contributor
to the destruction of cartilage, but treatment with LE and rLE
reduced the expression of MMP-3 in inflammatory articular
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Figure 2: Eﬀects of LE and rLE on the progression and severity of CIA in mice. LE and rLE at 10 mg/kg were orally administered to CII-
immunized mice once daily from day 25 to day 45. (a) The severity of arthritis was evaluated by clinical arthritis score and hind paw thickness.
Data are expressed as mean ± SE of 5 mice per group. ∗P < .05 versus vehicle-treated CIA mice. (b) Joint tissues from all mice were stained
with H&E for histopathological examination (upper) and immunohistochemically stained for MMP-3 expression (lower).
cartilage (Figure 2(b)). Therefore, rLE and LE are novel
potential anti-arthritic agents.
Similarly to human RA, the binding and accumulation of
anti-CII antibodies in the articular region of CII-immunized
mice may initiate inflammatory responses by activating
the complement cascade. The activation of the comple-
ment cascade results in the recruitment of neutrophils and
macrophages, which secrete chemotoxic materials and pro-
inflammatory cytokines, such as IL-1β, TNF-α, IL-8, IL-6,
nitric oxide, and prostaglandin E2 [18]. Of these, TNF-α
drives early joint inflammation and inflammatory cell infil-
tration into the synovial tissue, while IL-1β plays a pivotal
role in mediating cartilage degradation and bone erosion. In
particular, TNF-α has been considered as a therapeutic target
for RA [28]. Inflammatory cytokines such as TNF-α and IL-
1β stimulate the production of MMPs. Therefore, controlling
MMP activity as well as the production of pro-inflammatory
cytokines is required for the eﬀective treatment of arthritis.
In this study, TNF-α and IL-1β levels were measured in
the sera of control mice and CIA mice treated with vehicle,
LE or rLE on day 45. While TNF-α and IL-1β levels were
significantly increased in the sera of vehicle-treated CIA
mice, orally administrated LE and rLE inhibited the CIA-
induced increases in the serum levels of these cytokines
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Figure 3: Eﬀects of LE and rLE on the serum TNF-α and IL-1β levels, and pro-inflammatory immune response of spleen cell in CIA
mice. CIA mice with the clinical signs of arthritis were orally administered the vehicle (PBS containing 1% DMSO), LE (10 mg/kg) or rLE
(10 mg/kg) once daily from day 25 to day 45. Control mice were neither immunized with CII nor treated with extracts. (a) The serum levels
of TNF-α and IL-1β were measured by ELISA assay. (b) Single-cell suspensions from spleens were obtained from control and all CIA mice.
The proliferation of spleen cells stimulated with 50 μg/ml denatured CII for 72 hours was assessed using a BrdU cell proliferation ELISA kit
(left), and TNF-α and IL-1β levels were measured in conditioned media of spleen cells stimulated with 50 μg/ml denatured CII or 5 μg/ml
LPS for 48 hours, using each specific ELISA kit (middle and right). Data is expressed as mean ± SE of 5 mice per group. #P < .01 versus
control mice, ∗P < .01 versus vehicle-treated CIA mice.
(Figure 3(a)). These results suggest that LE and rLE may
ameliorate CIA by blocking the increased levels of TNF-α and
IL-1β in CIA mice.
The prevalence of CII-specific T cells, the primary
mediators of CIA induction, has been observed in the
early phase of RA [29]. Although the pathways that drive
cytokine release in RA synovium are still undefined, T cells
can regulate cytokine secretion by directly releasing IL-17
into the extracellular space or via cellular contacts with
synovial macrophages [28, 30]. To estimate the eﬀects of our
extracts on CII-specific T cell responses, cell proliferation
was investigated with spleen cells isolated from control
mice and CIA mice treated with vehicle, LE or rLE. The
spleen is the major site of adaptive immune response to
blood-borne antigens due to the high population of resident
phagocytes and lymphocytes. Spleen cells are stimulated with
either CII to activate T cells or LPS to potently activate
macrophages [16]. The proliferation of spleen cells from
vehicle-treated CIA mice was increased by CII stimulation
for 72 hours, but spleen cells from LE- and rLE-treated CIA
mice exhibited significantly less proliferation than those from
vehicle-treated CIA mice (see Figure 3(b)). Next, CII- and
LPS-induced cytokine levels were measured in spleen cells
from CIA mice treated with vehicle, LE and rLE. CII- or LPS-
stimulated secretion of TNF-α and IL-1β was also reduced in
spleen cells isolated from CIA mice treated with LE or rLE,
as compared to spleen cells from vehicle-treated CIA mice
(Figure 3(b)). These results suggest that LE and rLE alleviate
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Figure 4: Eﬀects of LE and rLE on oxidative tissue damages in CIA mice. MDA (a) and GSH (b) levels, and catalase activities (c) were
determined in liver and kidney tissues from control and CIA mice treated with vehicle, LE (10 mg/kg) or rLE (10 mg/kg) on day 45. Data is
expressed as mean ± SE of 5 mice per group. #P < .01 versus control mice, ∗P < .05 versus vehicle-treated mice.
CIA by reducing the immune responses of spleen cells, which
results in decreased cytokine production.
ROS released from infiltrating inflammatory cells is
implicated in the breakdown of cartilage and bone in RA,
and elevated levels of MDA have been observed in the
serum and synovial fluid of RA patients [31]. Moreover,
chronic inflammatory conditions reduce a body’s antiox-
idant capacity by aﬀecting a variety of endogenous ROS
scavenging proteins, enzymes, and chemical compounds.
This leads to oxidative stress, which damages other tissues
and organs [32]. Therefore, control of ROS levels is also
required to reduce CIA severity and tissue damage. To study
the protective eﬀects of LE and rLE on tissue oxidative
damages in CIA mice, MDA level as a marker of lipid
peroxidation, GSH content, and antioxidant enzyme activity
were measured in liver and kidney tissue homogenates from
control mice and CIA mice treated with vehicle, LE or
rLE. MDA levels were elevated in liver and kidney tissues
from vehicle-treated CIA mice, but the increase in MDA
levels was inhibited in those from LE or rLE-treated CIA
mice (Figure 4(a)). In addition, the decreased tissue GSH
levels (Figure 4(b)) and catalase activities (Figure 4(c)) in
vehicle-treated CIA mice were rescued by oral administration
of LE or rLE. These results suggest that LE and rLE
can prevent tissue damage by blocking oxidative stress in
CIA mice.
Journal of Biomedicine and Biotechnology 7
4. Conclusion
Topical application of LE or rLE onto the mouse ear prior to
TPA treatment inhibited TPA-induced acute inflammation,
and oral administration of LE or rLE eﬀectively suppressed
the inflammatory response and tissue damage in the CIA
mouse model. rLE exhibited a more potent inhibition on
TPA-induced acute inflammation than LE, but the anti-
arthritic eﬀect of rLE was similar to that of LE in the CIA
model. Overall, these data suggest that supplementation with
LE and rLE may be beneficial in preventing and treating both
acute and chronic inflammatory conditions.
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